Collegium Pharmaceutical, Inc. (COLL) Stock Forecast
COLL analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 8 analysts
- Price target
- $49.00 average of analyst targets
- Upside to target
- +111.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $1.53
- 52-week range
- $21.53 – $49.84
COLL analyst ratings
8 analystsNumber of analysts at each rating.
COLL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
COLL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.86 | $1.72 | $1.97 | $2.25 | −17.5% | 7 |
| Current fiscal year (2026) | $7.46 | $7.20 | $7.69 | $7.42 | +0.5% | 7 |
| Next fiscal year (2027) | $7.26 | $4.96 | $8.88 | $7.46 | −2.7% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
COLL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $216.0M | $214.0M | $221.2M | +3.2% | 7 |
| Current fiscal year (2026) | $833.1M | $826.0M | $837.3M | +6.7% | 7 |
| Next fiscal year (2027) | $844.5M | $727.4M | $883.0M | +1.4% | 7 |
COLL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
COLL revenue: reported and forecast
COLL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.10 | $1.87 | $1.82 | $1.80 | $1.86 | −11.5% | 0 up · 1 down |
| Current fiscal year (2026) | $7.78 | $7.53 | $7.37 | $7.34 | $7.46 | −4.2% | 0 up · 1 down |
| Next fiscal year (2027) | $7.51 | $6.97 | $6.62 | $6.65 | $7.26 | −3.4% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
COLL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; COLL beat in 10 of 12.
What analysts expect from COLL
8 analysts cover Collegium Pharmaceutical; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $49.00, 111.3% above the latest close of $23.19. Analysts expect earnings of $7.46 per share for 2026, +0.5% from a year earlier. For 2027 the average estimate is $7.26 per share on revenue of $844.5 million. Collegium Pharmaceutical beat the EPS estimate in 10 of the last 12 quarters.
Related: COLL income statement, COLL key metrics, COLL chart. See the COLL stock overview for the latest quote and news.
COLL forecast FAQ
What is Collegium Pharmaceutical's price target?
The average analyst price target for Collegium Pharmaceutical is $49.00, 111.3% above the latest close of $23.19.
Is Collegium Pharmaceutical a buy, hold or sell?
Of 8 analysts covering Collegium Pharmaceutical, 5 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Collegium Pharmaceutical's EPS forecast?
Analysts forecast $7.46 per share for 2026 (range $7.20 to $7.69); for 2027 the estimate is $7.26.
What is Collegium Pharmaceutical's revenue forecast?
The average revenue estimate for 2026 is $833.1 million, growth of 6.7%; for 2027 it is $844.5 million.
When does Collegium Pharmaceutical report earnings?
Collegium Pharmaceutical is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $1.53.
Does Collegium Pharmaceutical usually beat earnings estimates?
Collegium Pharmaceutical reported EPS at or above the analyst estimate in 10 of the last 12 quarters.